Huanyu Ren, Lina Zou, Lan Jiang, Ping Zhang, Chunmei Li, Zheng Li, Huiru Niu, Xiaojing Zhang, Hao Liao, Lang Cheng, Feiyan Yang, Shanshan An, Xiuhong Ge, Fei Ren, Hongzhi Pan, Shengzhong Rong, Hongkun Ma
{"title":"环状RNA和RNA甲基化酶在膀胱癌预后中的作用：中国研究的系统回顾和荟萃分析。","authors":"Huanyu Ren, Lina Zou, Lan Jiang, Ping Zhang, Chunmei Li, Zheng Li, Huiru Niu, Xiaojing Zhang, Hao Liao, Lang Cheng, Feiyan Yang, Shanshan An, Xiuhong Ge, Fei Ren, Hongzhi Pan, Shengzhong Rong, Hongkun Ma","doi":"10.1016/j.urolonc.2025.06.005","DOIUrl":null,"url":null,"abstract":"<p><p>In recent years, some circRNAs and RNA methylation enzymes (including RNA methyltransferases and RNA demethylases) have been reported to be associated to the prognosis of bladder cancer, but the findings have been inconsistent. Therefore, the aims of this study is to comprehensively evaluate the prognostic value of circRNAs and RNA methylation enzymes as a whole in bladder cancer by Meta-analysis. A comprehensive literature search was performed in PubMed, Cochrane Library, EMbase, Web of Science, CNKI, WanFang, and VIP databases from the establishment of the database to March 2024. Data were extracted from the included literature and statistically analyzed using Stata 18.0 MP. (1) Overall survival (OS): high expression of circRNAs decreased OS of bladder cancer (HR = 1.74, 95% CI: 1.26-2.41, P = 0.001); and high fat mass and obesity-associated protein (FTO) expression led to poor OS in bladder cancer (HR = 2.38, 95% CI: 1.08-2.25, P = 0.032). (2) Disease-free survival (DFS): low circRNAs expression resulted in poor DFS (HR = 1.74, 95% CI: 1.38-2.18, P < 0.001); (3) Recurrence-free survival (RFS): high expression of circ-CCT3 and circ-RHOT1 decreased bladder cancer patients' RFS (HR = 2.26, 95% CI: 1.63-3.12, P < 0.001); and low expression of circ0004826 and circ0077837 also affected RFS (HR = 0.19, 95% CI: 0.08-0.43, P < 0.001). (4) 5-year survival: high expression of circRNAs decreased 5-year survival of bladder cancer patients (HR = 3.26, 95% CI: 1.90-5.57, P < 0.001). CircRNAs and FTO can be prognostic factors for bladder cancer.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognostic role of circRNAs and RNA methylation enzymes in bladder cancer: A systematic review and meta-analysis of Chinese studies.\",\"authors\":\"Huanyu Ren, Lina Zou, Lan Jiang, Ping Zhang, Chunmei Li, Zheng Li, Huiru Niu, Xiaojing Zhang, Hao Liao, Lang Cheng, Feiyan Yang, Shanshan An, Xiuhong Ge, Fei Ren, Hongzhi Pan, Shengzhong Rong, Hongkun Ma\",\"doi\":\"10.1016/j.urolonc.2025.06.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In recent years, some circRNAs and RNA methylation enzymes (including RNA methyltransferases and RNA demethylases) have been reported to be associated to the prognosis of bladder cancer, but the findings have been inconsistent. Therefore, the aims of this study is to comprehensively evaluate the prognostic value of circRNAs and RNA methylation enzymes as a whole in bladder cancer by Meta-analysis. A comprehensive literature search was performed in PubMed, Cochrane Library, EMbase, Web of Science, CNKI, WanFang, and VIP databases from the establishment of the database to March 2024. Data were extracted from the included literature and statistically analyzed using Stata 18.0 MP. (1) Overall survival (OS): high expression of circRNAs decreased OS of bladder cancer (HR = 1.74, 95% CI: 1.26-2.41, P = 0.001); and high fat mass and obesity-associated protein (FTO) expression led to poor OS in bladder cancer (HR = 2.38, 95% CI: 1.08-2.25, P = 0.032). (2) Disease-free survival (DFS): low circRNAs expression resulted in poor DFS (HR = 1.74, 95% CI: 1.38-2.18, P < 0.001); (3) Recurrence-free survival (RFS): high expression of circ-CCT3 and circ-RHOT1 decreased bladder cancer patients' RFS (HR = 2.26, 95% CI: 1.63-3.12, P < 0.001); and low expression of circ0004826 and circ0077837 also affected RFS (HR = 0.19, 95% CI: 0.08-0.43, P < 0.001). (4) 5-year survival: high expression of circRNAs decreased 5-year survival of bladder cancer patients (HR = 3.26, 95% CI: 1.90-5.57, P < 0.001). CircRNAs and FTO can be prognostic factors for bladder cancer.</p>\",\"PeriodicalId\":23408,\"journal\":{\"name\":\"Urologic Oncology-seminars and Original Investigations\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-06-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Urologic Oncology-seminars and Original Investigations\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.urolonc.2025.06.005\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologic Oncology-seminars and Original Investigations","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.urolonc.2025.06.005","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
近年来，一些circrna和RNA甲基化酶（包括RNA甲基转移酶和RNA去甲基化酶）被报道与膀胱癌的预后相关，但研究结果并不一致。因此，本研究的目的是通过meta分析综合评价circRNAs和RNA甲基化酶在膀胱癌中的预后价值。全面检索PubMed、Cochrane Library、EMbase、Web of Science、CNKI、万方、VIP等数据库自建库至2024年3月的文献。数据从纳入的文献中提取，并使用Stata 18.0 MP进行统计分析。(1)总生存期（OS）：高表达circRNAs可降低膀胱癌的OS (HR = 1.74, 95% CI: 1.26-2.41, P = 0.001)；高脂肪量和肥胖相关蛋白（FTO）表达导致膀胱癌OS较差（HR = 2.38, 95% CI: 1.08-2.25, P = 0.032）。(2)无病生存（DFS）：低circRNAs表达导致低DFS (HR = 1.74, 95% CI: 1.38 ~ 2.18, P < 0.001)；(3)无复发生存期（RFS）： circ-CCT3和circ-RHOT1高表达可降低膀胱癌患者的RFS (HR = 2.26, 95% CI: 1.63 ~ 3.12, P < 0.001)；circ0004826和circ0077837的低表达也影响RFS （HR = 0.19, 95% CI: 0.08 ~ 0.43, P < 0.001）。(4) 5年生存率：circRNAs高表达降低膀胱癌患者5年生存率（HR = 3.26, 95% CI: 1.90 ~ 5.57, P < 0.001）。circrna和FTO可能是膀胱癌的预后因素。
Prognostic role of circRNAs and RNA methylation enzymes in bladder cancer: A systematic review and meta-analysis of Chinese studies.
In recent years, some circRNAs and RNA methylation enzymes (including RNA methyltransferases and RNA demethylases) have been reported to be associated to the prognosis of bladder cancer, but the findings have been inconsistent. Therefore, the aims of this study is to comprehensively evaluate the prognostic value of circRNAs and RNA methylation enzymes as a whole in bladder cancer by Meta-analysis. A comprehensive literature search was performed in PubMed, Cochrane Library, EMbase, Web of Science, CNKI, WanFang, and VIP databases from the establishment of the database to March 2024. Data were extracted from the included literature and statistically analyzed using Stata 18.0 MP. (1) Overall survival (OS): high expression of circRNAs decreased OS of bladder cancer (HR = 1.74, 95% CI: 1.26-2.41, P = 0.001); and high fat mass and obesity-associated protein (FTO) expression led to poor OS in bladder cancer (HR = 2.38, 95% CI: 1.08-2.25, P = 0.032). (2) Disease-free survival (DFS): low circRNAs expression resulted in poor DFS (HR = 1.74, 95% CI: 1.38-2.18, P < 0.001); (3) Recurrence-free survival (RFS): high expression of circ-CCT3 and circ-RHOT1 decreased bladder cancer patients' RFS (HR = 2.26, 95% CI: 1.63-3.12, P < 0.001); and low expression of circ0004826 and circ0077837 also affected RFS (HR = 0.19, 95% CI: 0.08-0.43, P < 0.001). (4) 5-year survival: high expression of circRNAs decreased 5-year survival of bladder cancer patients (HR = 3.26, 95% CI: 1.90-5.57, P < 0.001). CircRNAs and FTO can be prognostic factors for bladder cancer.
期刊介绍：
Urologic Oncology: Seminars and Original Investigations is the official journal of the Society of Urologic Oncology. The journal publishes practical, timely, and relevant clinical and basic science research articles which address any aspect of urologic oncology. Each issue comprises original research, news and topics, survey articles providing short commentaries on other important articles in the urologic oncology literature, and reviews including an in-depth Seminar examining a specific clinical dilemma. The journal periodically publishes supplement issues devoted to areas of current interest to the urologic oncology community. Articles published are of interest to researchers and the clinicians involved in the practice of urologic oncology including urologists, oncologists, and radiologists.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
